Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Hirase
Pdb62 - Cost-Effectiveness Analysis of Empagliflozin in Japan Based on Results From the Subgroup Analysis of Asian Patients in the Empa-Reg Outcome Trial
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pdb63 - Cost-Effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of Empa-Reg Outcome in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Following the Results of the EMPA-REG OUTCOME Trial With Empagliflozin, Is It Possible to Speak of a Class Effect?
International Journal of General Medicine
Medicine
Pdb76 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Liraglutide Based on Cardiovascular Outcome Trials
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Ce1 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
Diabetes Technology and Therapeutics
Medicine
Endocrinology
Medical Laboratory Technology
Metabolism
Diabetes
DECLARE-TIMI 58 Trial in the Context of EMPA-REG OUTCOME and CANVAS
Diabetes Mellitus
Internal Medicine
Endocrinology
Metabolism
Diabetes
Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME
Metabolism: Clinical and Experimental
Endocrinology
Metabolism
Diabetes
EMPA-REG OUTCOME: The Endocrinologist's Point of View
American Journal of Medicine
Medicine
